2. Search Result
Search Result
Results for "

oral ulceration

" in MedChemExpress (MCE) Product Catalog:

45

Inhibitors & Agonists

1

Fluorescent Dye

1

Biochemical Assay Reagents

2

Peptides

10

Natural
Products

2

Isotope-Labeled Compounds

1

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-141521
    Amelenodor
    1 Publications Verification

    NX-13

    		 NOD-like Receptor (NLR) Inflammation/Immunology
    NX-13 is a first-in-class, orally active and gut-restricted agent that selectively targets and activates the NLRX1 pathway to induce immunometabolic changes. NX-13 results in lower inflammation and responses in inflammatory bowel disease. NX-13 can be used for the research of crohn's disease and ulcerative colitis .
    Amelenodor
  • HY-145697
    GPR84 antagonist 2

    		GPR84 Inflammation/Immunology
    GPR84 antagonist 2 (compound 33) is a potent, selective, and orally active GPR84 antagonist (IC50=8.95 nM). GPR84 antagonist 2 shows improved potency in the calcium mobilization assay and the ability to inhibit the chemotaxis of neutrophils and macrophages upon GPR84 activation. GPR84 antagonist 2 has the potential for the research of ulcerative colitis .
    GPR84 antagonist 2
  • HY-B0996
    Hexetidine

    NSC-17764

    		 Bacterial Fungal Infection Inflammation/Immunology
    Hexetidine (NSC-17764) is an orally active antibacterial and antifungal agent with broad antibacterial and antifungal activity. Hexetidine combined with IPBC potentiates strong fungal growth inhibition properties. Hexetidine at concentrations greater than 0.1% can cause oral ulceration. Additionally, Hexetidine improves its plaque inhibiting activities combined with zinc and has been confirmed the effectiveness on purulent wound along with ultrasound. Hexetidine is a promising candidate for research in fungus-related diseases and soft tissue purulent-inflammatory
    Hexetidine
  • HY-106359A
    Delmitide acetate

    RDP-58 acetate

    		 TNF Receptor IFNAR Reactive Oxygen Species (ROS) Cancer
    Delmitide (RDP58) acetate is an orally active d-isomer decapeptide with potent anti-inflammatory activity. Delmitide acetate inhibits production of TNF-α, IFN-γ, and interleukin (IL)-12, and up-regulates heme oxygenase 1 activity. Delmitide acetate can be used for the research of ulcerative colitis .
    Delmitide acetate
  • HY-B1367
    Carbenoxolone disodium
    Maximum Cited Publications
    8 Publications Verification

    		 Gap Junction Protein Orthopoxvirus 11β-HSD Infection Inflammation/Immunology
    Carbenoxolone disodium is the active metabolite of Glycyrrhizic acid (HY-N0184) and the inhibitor of human 11β-HSD and bacterial 3α, 20β-HSD . Carbenoxolone disodium is an uncoupling agent for gap junctions and a potent inhibitor of Vaccinia virus replication . Carbenoxolone disodium is used for the study of peptic, esophageal and oral ulceration and inflammation. Carbenoxolone disodium inhibits Vaccinia virus replication.
    Carbenoxolone disodium
  • HY-132831
    Selnoflast
    1 Publications Verification

    Somalix; RO-7486967; IZD334

    		 NOD-like Receptor (NLR) Interleukin Related Neurological Disease Inflammation/Immunology
    Selnoflast (RO7486967), formerly somalix/RG6418/IZD334, is an orally active, potent, selective and reversible small molecule NLRP3 inflammasome inhibitor. Selnoflast is a potent inhibitor of IL-1β release stimulated by NLRP3 activation in human Alzheimer's disease (AD) monocyte-derived macrophages. Selnoflast is promising for research of AD and systemic inflammatory diseases, such as ulcerative colitis and chronic obstructive pulmonary disease .
    Selnoflast
  • HY-145829
    Tofacitinib Prodrug-1

    		JAK Apoptosis Inflammation/Immunology
    Tofacitinib precursor-1 is an effective and oral active precursor to mitigate the systemic adverse effects of Tofacitinib. Tofacitinib precursor-1 can effectively attenuate the oxazolone-induced colitis in mice model with low toxicity. Tofacitinib precursor-1 is a potential drug candidate for the research of ulcerative colitis .
    Tofacitinib Prodrug-1
  • HY-176305S
    Neurofilament, U-15N

    		Isotope-Labeled Compounds Neurological Disease
    Neurofilament, U- 15N is the 15N-labeled Neurofilament.
    Neurofilament, U-15N
  • HY-162710
    LTA4H-IN-5

    		Aminopeptidase Inflammation/Immunology
    LTA4H-IN-5 (Compound H122) is an orally active inhibitor for leukotriene A4 hydrolase (LTA4H), that inhibits the LTA4H aminopeptidase and LTA4H hydrolase with IC50 of 0.38 nM and 16.93 nM. LTA4H-IN-5 exhibits good pharmacokinetic characteristics in C57 mice and ameliorates the DNBS-induced ulcerative enteritis in rat models .
    LTA4H-IN-5
  • HY-106359
    Delmitide

    RDP-58

    		 TNF Receptor IFNAR Reactive Oxygen Species (ROS) Infection Inflammation/Immunology Cancer
    Delmitide (RDP58) is an orally active d-isomer decapeptide with potent anti-inflammatory activity. Delmitide inhibits production of TNF-α, IFN-γ, and interleukin (IL)-12, and up-regulates heme oxygenase 1 activity. Delmitide can be used for the research of ulcerative colitis .
    Delmitide
  • HY-10053
    Maropitant

    		Neurokinin Receptor Neurological Disease Endocrinology
    Maropitant is an orally active NK1 receptor antagonist. Maropitant prevents vomiting and inhibits ulcerative dermatitis .
    Maropitant
  • HY-10053B
    Maropitant citrate

    		Neurokinin Receptor Neurological Disease Inflammation/Immunology
    Maropitant citrate is an orally active NK1 receptor antagonist. Maropitant citrate prevents vomiting and inhibits ulcerative dermatitis .
    Maropitant citrate
  • HY-109148
    Izencitinib

    TD-1473; JNJ-8398

    		 JAK Inflammation/Immunology
    Izencitinib (TD-1473) is an orally active, non-selective and gut-restricted JAK inhibitor. Izencitinib (TD-1473) can be used in the study for ulcerative colitis .
    Izencitinib
  • HY-14857
    Carotegrast

    HCA2969

    		 Integrin Inflammation/Immunology
    Carotegrast (HCA2969) is an orally active α4 integrin inhibitor with anti-inflammatory activity. Carotegrast can be used in the research of inflammation-related diseases, such as ulcerative colitis .
    Carotegrast
  • HY-N0586A
    Norisoboldine hydrochloride

    (+)-Laurelliptine hydrochloride

    		 Adenosine Receptor Inflammation/Immunology
    Norisoboldine hydrochloride is an orally active natural aryl hydrocarbon receptor (AhR) agonist. Norisoboldine hydrochloride, as a major isoquinoline alkaloid present in Radix Linderae, can be used for the research of Rheumatoid arthritis and Ulcerative colitis .
    Norisoboldine hydrochloride
  • HY-N0586
    Norisoboldine

    (+)-Laurelliptine

    		 Adenosine Receptor Inflammation/Immunology
    Norisoboldine is an orally active natural aryl hydrocarbon receptor (AhR) agonist. Norisoboldine, as a major isoquinoline alkaloid present in Radix Linderae, can be used for the research of Rheumatoid arthritis and Ulcerative colitis .
    Norisoboldine
  • HY-108278
    Zolimidine

    		Drug Derivative Endocrinology
    Zolimidine, a derivate of imidazopyridine, is an orally active antiulcer agent. Zolimidine stimulates mucus secretion in intestinal mucosal cells and enhacnes intestinal wall more resistant to ulceration. Zolimidine exhibits gastroprotective effect in duodenal ulcer research .
    Zolimidine
  • HY-131969
    ASK1-IN-2

    		ASK1 MAP3K Apoptosis Inflammation/Immunology
    ASK1-IN-2 is a potent and orally active inhibitor of apoptosis signal-regulating kinase 1 (ASK1), with an IC50 of 32.8 nM. ASK1-IN-2 can be used for the research of ulcerative colitis .
    ASK1-IN-2
  • HY-B0954A
    Oxyphencyclimine

    		mAChR Endocrinology
    Oxyphencyclimine is an orally active muscarinic receptor (mAChR) antagonist. Oxyphencyclimine is effective in reducing ulceration index and increasing pepsin activity in rat gastric ulcer model. Oxyphencyclimine can be used in studies of peptic ulcer disease and gastrointestinal spasm .
    Oxyphencyclimine
  • HY-174976
    FHND5032

    		PI3K Akt Interleukin Related Bacterial Inflammation/Immunology
    FHND5032 is an orally active miR-124 inducer. FHND5032 significantly upregulates miR-124 expression in macrophages. FHND5032 disrupts inflammatory signaling, promotes macrophage reprogramming, and restores the epithelial barrier function by inhibiting the PIK3R2/PI3K/Akt axis. FHND5032 alleviates colitis and reduces inflammatory burden in ulcerative colitis mice. FHND5032 can be used for the study of ulcerative colitis .
    FHND5032
  • HY-N0586R
    Norisoboldine (Standard)

    (+)-Laurelliptine (Standard)

    		 Reference Standards Adenosine Receptor Inflammation/Immunology
    Norisoboldine (Standard) is the analytical standard of Norisoboldine. This product is intended for research and analytical applications. Norisoboldine is an orally active natural aryl hydrocarbon receptor (AhR) agonist. Norisoboldine, as a major isoquinoline alkaloid present in Radix Linderae, can be used for the research of Rheumatoid arthritis and Ulcerative colitis .
    Norisoboldine (Standard)
  • HY-N2551
    Vitamin U chloride

    S-Methylmethionine sulfonium chloride

    		 Others Inflammation/Immunology
    Vitamin U (S-Methylmethionine sulfonium) chloride is an orally active anti-ulcer agent with antioxidant activity. Vitamin U inhibits adipocyte differentiation. Vitamin U promotes skin wound healing.Vitamin U can be used in the research of gastrointestinal ulceration .
    Vitamin U chloride
  • HY-B1402B
    Hydrocortisone hemisuccinate sodium
    1 Publications Verification

    Hydrocortisone 21-hemisuccinate sodium

    		 Glucocorticoid Receptor Cardiovascular Disease Metabolic Disease
    Hydrocortisone hemisuccinate sodium is an orally active physiological glucocorticoid. Hydrocortisone hemisuccinate sodium inhibits proinflammatory cytokine activity, with IC50s of 6.7 and 21.4 μM for IL-6 and IL-3, respectively. Hydrocortisone hemisuccinate sodium can be used for the research of ulcerative colitis (UC) .
    Hydrocortisone hemisuccinate sodium
  • HY-B1402
    Hydrocortisone hemisuccinate
    1 Publications Verification

    Hydrocortisone 21-hemisuccinate

    		 Interleukin Related Cardiovascular Disease Metabolic Disease Inflammation/Immunology Endocrinology
    Hydrocortisone hemisuccinate (Hydrocortisone 21-hemisuccinate), a glucocorticoid, is an orally active steroidal anti-inflammatory agent (SAID) with anti-inflammatory and immunomodulatory activities. Hydrocortisone hemisuccinate inhibits the bioactivity of IL-6 and IL-3 with IC50 values of 6.7 and 21.4 μM, respectively. Hydrocortisone hemisuccinate can be used in the study of ulcerative colitis (UC) and recurrent oral ulcers .
    Hydrocortisone hemisuccinate
  • HY-B1402A
    Hydrocortisone hemisuccinate hydrate

    Hydrocortisone 21-hemisuccinate hydrate

    		 Interleukin Related Inflammation/Immunology Endocrinology
    Hydrocortisone hemisuccinate hydrate (Hydrocortisone 21-hemisuccinate hydrate), a glucocorticoid, is an orally active steroidal anti-inflammatory agent (SAID) with anti-inflammatory and immunomodulatory activities. Hydrocortisone hemisuccinate hydrate inhibits the bioactivity of IL-6 and IL-3 with IC50 values of 6.7 and 21.4 μM, respectively. Hydrocortisone hemisuccinate hydrate can be used in the study of ulcerative colitis (UC) and recurrent oral ulcers .
    Hydrocortisone hemisuccinate hydrate
  • HY-106054
    Nocloprost

    		Prostaglandin Receptor Metabolic Disease Inflammation/Immunology
    Nocloprost, a prostaglandin E2 (PGE2) analog, is an orally active EP1- and EP3-receptor agonist. Nocloprost inhibits evoked [ 3H]ACh release. Nocloprost has gastroprotective and ulcer-healing properties. Nocloprost accelerates the healing of chronic gastric ulcerations and enhances mucosal growth in rats .
    Nocloprost
  • HY-151252
    NIC-0102

    		Proteasome NOD-like Receptor (NLR) Inflammation/Immunology
    NIC-0102 is an orally active proteasome inhibitor (pIC50=7.55) that specifically inhibits NLRP3 inflammatory vesicle activation. NIC-0102 shows potent anti-inflammatory effects in a model of dextran sulfate sodium (DSS)-induced ulcerative colitis. NIC-0102 also inhibits production of pro-IL-1β .
    NIC-0102
  • HY-174159
    COX-2-IN-54

    		COX Inflammation/Immunology
    COX-2-IN-54 (Compound 7y) is an orally active COX-2 inhibitor with an IC50 of 4.15 μM. COX-2-IN-54 has a strong protective effect against DSS-induced ulcerative colitis and can significantly reduce tissue damage. COX-2-IN-54 has anti-inflammatory activity .
    COX-2-IN-54
  • HY-103377
    Antalarmin hydrochloride
    3 Publications Verification

    		 CRFR Inflammation/Immunology Endocrinology
    Antalarmin (hydrochloride) is an oral active non-peptide corticotropin-releasing hormone receptor 1 (CRHR1) antagonist with a Ki of 1 nM. Antalarmin hydrochloride suppresses CRH-induced ACTH secretion and blocks CRH and novelty induced anxiety-like behavior in animal models. Antalarmin hydrochloride produces anti-inflammatory effects in arthritis models, and suppresses stress-induced gastric ulceration related to irritable bowel syndrome .
    Antalarmin hydrochloride
  • HY-103377R
    Antalarmin hydrochloride (Standard)

    		Reference Standards CRFR Inflammation/Immunology Endocrinology
    Antalarmin (hydrochloride) (Standard) is the analytical standard of Antalarmin (hydrochloride). This product is intended for research and analytical applications. Antalarmin (hydrochloride) is an oral active non-peptide corticotropin-releasing hormone receptor 1 (CRHR1) antagonist with a Ki of 1 nM. Antalarmin hydrochloride suppresses CRH-induced ACTH secretion and blocks CRH and novelty induced anxiety-like behavior in animal models. Antalarmin hydrochloride produces anti-inflammatory effects in arthritis models, and suppresses stress-induced gastric ulceration related to irritable bowel syndrome .
    Antalarmin hydrochloride (Standard)
  • HY-B1402R
    Hydrocortisone hemisuccinate (Standard)

    Hydrocortisone 21-hemisuccinate (Standard)

    		 Reference Standards Glucocorticoid Receptor Interleukin Related Metabolic Disease Inflammation/Immunology Endocrinology
    Hydrocortisone hemisuccinate (Standard) is the analytical standard of Hydrocortisone hemisuccinate. This product is intended for research and analytical applications. Hydrocortisone hemisuccinate (Hydrocortisone 21-hemisuccinate), a physiological glucocorticoid, is an orally active steroidal anti-in ammatory agent (SAID). Hydrocortisone hemisuccinate inhibits proinflammatory cytokine activity, with IC50s of 6.7 and 21.4 μM for IL-6 and IL-3, respectively. Hydrocortisone hemisuccinate can be used for the research of ulcerative colitis (UC).
    Hydrocortisone hemisuccinate (Standard)
  • HY-132831B
    Selnoflast potassium

    Somalix potassium; RO-7486967 potassium; IZD334 potassium

    		 NOD-like Receptor (NLR) Interleukin Related Neurological Disease Inflammation/Immunology
    Selnoflast potassium (RO7486967 potassium), formerly somalix/RG6418/IZD334, is an orally active, potent, selective and reversible small molecule NLRP3 inflammasome inhibitor. Selnoflast potassium is a potent inhibitor of IL-1β release stimulated by NLRP3 activation in human Alzheimer's disease (AD) monocyte-derived macrophages. Selnoflast potassium is promising for research of AD and systemic inflammatory diseases, such as ulcerative colitis and chronic obstructive pulmonary disease .
    Selnoflast potassium
  • HY-B1402G
    Hydrocortisone hemisuccinate

    Hydrocortisone 21-hemisuccinate

    		 Interleukin Related Metabolic Disease Inflammation/Immunology Endocrinology
    Hydrocortisone hemisuccinate GMP (Hydrocortisone 21-hemisuccinate GMP) is a GMP-grade version of Hydrocortisone hemisuccinate (HY-B1402). GMP-grade small molecules can be used as auxiliary reagents in cell therapy. Hydrocortisone hemisuccinate (Hydrocortisone 21-hemisuccinate), a glucocorticoid, is an orally active steroidal anti-inflammatory agent (SAID) with anti-inflammatory and immunomodulatory activities. Hydrocortisone hemisuccinate inhibits the bioactivity of IL-6 and IL-3 with IC50 values of 6.7 and 21.4 μM, respectively. Hydrocortisone hemisuccinate can be used in the study of ulcerative colitis (UC) and recurrent oral ulcers . .
    Hydrocortisone hemisuccinate
  • HY-132831A
    Selnoflast calcium

    Somalix calcium; RO-7486967 calcium; IZD334 calcium

    		 NOD-like Receptor (NLR) Interleukin Related Neurological Disease Inflammation/Immunology
    Selnoflast calcium (RO7486967 calcium), formerly somalix/RG6418/IZD334, is an orally active, potent, selective and reversible small molecule NLRP3 inflammasome inhibitor. Selnoflast calcium is a potent inhibitor of IL-1β release stimulated by NLRP3 activation in human Alzheimer's disease (AD) monocyte-derived macrophages. Selnoflast calcium is promising for research of AD and systemic inflammatory diseases, such as ulcerative colitis and chronic obstructive pulmonary disease .
    Selnoflast calcium
  • HY-143885
    JAK1/TYK2-IN-3

    		JAK Inflammation/Immunology
    JAK1/TYK2-IN-3 is a potent, selective and orally active dual TYK2/JAK1 inhibitor with IC50 values of 6 and 37 nM, respectively. JAK1/TYK2-IN-3 also shows selectively relative to JAK2 (IC50=140 nM) and JAK3 (IC50=362 nM). JAK1/TYK2-IN-3 shows anti-inflammatory effect by regulating the expression of related TYK2/JAK1-regulated genes, as well as the formation of Th1, Th2, and Th17 cells .
    JAK1/TYK2-IN-3
  • HY-N0433
    Astragaloside II
    1 Publications Verification

    Astrasieversianin VIII

    		 Autophagy Interleukin Related HIF/HIF Prolyl-Hydroxylase SOD NF-κB Inflammation/Immunology Endocrinology Cancer
    Astragaloside II is an orally active Cycloartane-type triterpene glycoside. Astragaloside II can be extracted from Astragalus membranaceus. Astragaloside II inhibits Autophagy, decreases pro-inflammatory cytokines (IL-6, IL-1β), HIF-α, p-p65, p-IκB and increases SOD. Astragaloside II regulates immunity and reduces inflammatory responses. Astragaloside II can be used in the research of diseases such as liver cancer, osteoporosis, immunosuppressive diseases, and ulcerative colitis .
    Astragaloside II
  • HY-N0671
    Rhapontin
    2 Publications Verification

    Rhaponiticin

    		 Apoptosis Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
    Rhapontin (Rhaponiticin) is an orally aactive SIRT1 agonist and AMPK activator with anti-inflammatory and anti-fibrotic activities. Rhapontin inhibits NLRP3 inflammasome activation by activating SIRT1 and inhibits TGF-β/Smad signaling via the AMPK pathway. Rhapontin reduces intestinal and lung inflammation, inhibits fibroblast differentiation and extracellular matrix deposition, and enhances tight junction protein expression to repair epithelial barriers. Rhapontin can be used in the study of inflammatory bowel diseases (such as ulcerative colitis) and pulmonary fibrosis .
    Rhapontin
  • HY-108039
    Bezisterim

    HE 3286; NE-3107

    		 NF-κB Neurological Disease Metabolic Disease Inflammation/Immunology
    Bezisterim (HE 3286; NE-3107) is a synthetic derivative of a natural anti-inflammatory steroid, β-AET. Bezisterim is an orally active partial NF-κB inhibitor. HE3286 reduces proinflammatory signals, including IL-6 and matrix metallopeptidase 3. Bezisterim freely penetrates the blood brain barrier in mice. Bezisterim can be used for the research of the ulcerative colitis, arthritis, experimental autoimmune encephalomyelitis . Bezisterim is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Bezisterim
  • HY-172871
    Anti-inflammatory agent 102

    		MAP3K p38 MAPK NF-κB Reactive Oxygen Species (ROS) NO Synthase Interleukin Related Inflammation/Immunology
    Anti-inflammatory agent 102 (Compound 11a) is an orally active anti-inflammatory agent. Anti-inflammatory agent 102 exerts its anti-inflammatory effect by blocking the activation of the ASK1/p38 MAPKs/NF-κB signaling pathway. Anti-inflammatory agent 102 has significant anti-inflammatory activity and can inhibit the release of NO, ROS, and inflammatory factors (such as IL-6, TNF-α, IL-1β). Anti-inflammatory agent 102 can be used in the study of inflammatory diseases such as ulcerative colitis (UC) .
    Anti-inflammatory agent 102
  • HY-126066
    (-)-Syringaresinol

    		Drug Isomer NO Synthase NF-κB TNF Receptor Interleukin Related IFNAR COX CD20 CDK Bcl-2 Family Apoptosis Akt p38 MAPK GSK-3 Neurological Disease Inflammation/Immunology Cancer
    (-)-Syringaresinol is an orally active isomer of syringaresinol (HY-N8307) found in Annona Montana. (-)-Syringaresinol exhibits antioxidant, anti-inflammatory, and anticancer activities. (-)-Syringaresinol can alleviate ulcerative colitis via the PI3K-Akt/MAPK/Wnt signaling pathway. (-)-Syringaresinol inhibits HL-60 cell proliferation by arresting the G1 phase and inducing apoptosis. (-)-Syringaresinol inhibits LPS (HY-D1056)-induced microglial activation by downregulating the NF-κB p65 signaling pathway and its interaction with ERβ, exerting anti-neuroinflammatory effects .
    (-)-Syringaresinol
  • HY-N0671R
    Rhapontin (Standard)
    2 Publications Verification

    Rhaponiticin (Standard)

    		 Reference Standards Apoptosis Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
    Rhapontin (Standard) is the analytical standard of Rhapontin (HY-N0671). This product is intended for research and analytical applications. Rhapontin (Rhaponiticin) is an orally aactive SIRT1 agonist and AMPK activator with anti-inflammatory and anti-fibrotic activities. Rhapontin inhibits NLRP3 inflammasome activation by activating SIRT1 and inhibits TGF-β/Smad signaling via the AMPK pathway. Rhapontin reduces intestinal and lung inflammation, inhibits fibroblast differentiation and extracellular matrix deposition, and enhances tight junction protein expression to repair epithelial barriers. Rhapontin can be used in the study of inflammatory bowel diseases (such as ulcerative colitis) and pulmonary fibrosis .
    Rhapontin (Standard)
  • HY-N7635
    Oleanolic acid 28-O-β-D-glucopyranoside

    β-D-Glucopyranosyl oleanolate

    		 NO Synthase COX Interleukin Related Claudin p38 MAPK Akt PI3K Inflammation/Immunology
    Oleanolic acid 28-O-β-D-glucopyranoside (β-D-Glucopyranosyl oleanolate) is an orally active pentacyclic triterpenoid compound. Oleanolic acid 28-O-β-D-glucopyranoside has anti-inflammatory effects. In ulcerative colitis models, Oleanolic acid 28-O-β-D-glucopyranoside can inhibit the inflammatory response, enhance the intestinal epithelial barrier function, and modulate the gut microbiota. Its mechanism of action is related to the PI3K-AKT and MAPK signaling pathways. Oleanolic acid 28-O-β-D-glucopyranoside can be used in the research of diseases such as colitis .
    Oleanolic acid 28-O-β-D-glucopyranoside
  • HY-150612
    (R)-STU104

    		p38 MAPK Cancer
    (R)-STU104 is a potent and orally active TAK1-MKK3 interaction inhibitor with IC50s of 0.58 μM and 4.0 μM for TNF-α and MKK3 phosphorylation. (R)-STU104 suppresses the TAK1/MKK3/p38/MnK1/MK2/elF4E signal pathways through binding with MKK3 and disrupting the TAK1 phosphorylating MKK3. (R)-STU104 can be used for researching ulcerative colitis .
    (R)-STU104
  • HY-N0433R
    Astragaloside II (Standard)

    Astrasieversianin VIII (Standard)

    		 Reference Standards Autophagy Interleukin Related HIF/HIF Prolyl-Hydroxylase SOD NF-κB Inflammation/Immunology Endocrinology Cancer
    Astragaloside II (Standard) is the analytical standard of Astragaloside II (HY-N0433). This product is intended for research and analytical applications. Astragaloside II is an orally active Cycloartane-type triterpene glycoside. Astragaloside II can be extracted from Astragalus membranaceus. Astragaloside II inhibits Autophagy, decreases pro-inflammatory cytokines (IL-6, IL-1β), HIF-α, p-p65, p-IκB and increases SOD. Astragaloside II regulates immunity and reduces inflammatory responses. Astragaloside II can be used in the research of diseases such as liver cancer, osteoporosis, immunosuppressive diseases, and ulcerative colitis .
    Astragaloside II (Standard)
  • HY-150612S
    (R)-STU104-d6

    		Isotope-Labeled Compounds p38 MAPK Cancer
    (R)-STU104-d6 is a deuterium labeled (R)-STU104 (HY-150612). (R)-STU104 is a potent and orally active TAK1-MKK3 interaction inhibitor with IC50s of 0.58 μM and 4.0 μM for TNF-α and MKK3 phosphorylation. (R)-STU104 suppresses the TAK1/MKK3/p38/MnK1/MK2/elF4E signal pathways through binding with MKK3 and disrupting the TAK1 phosphorylating MKK3. (R)-STU104 can be used for researching ulcerative colitis .
    (R)-STU104-d6

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: